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Abstract
Genome-wide association studies (GWAS) identified associations between markers within the
solute carrier family 14 (urea transporter), member 1 (SLC14A1) gene and risk of bladder cancer.
SLC14A1 defines the Kidd blood groups in erythrocytes and is also involved in concentration of
the urine in the kidney. We evaluated the association between a representative genetic variant
(rs10775480) of SLC14A1 and urine concentration, as measured by urinary specific gravity
(USG), in a subset of 275 population-based controls enrolled in the New England Bladder Cancer
Study. Overnight urine samples were collected and USG was measured using refractometry.
Analysis of covariance was used to estimate adjusted least square means for USG in relation to
rs10775480. We also examined the mRNA expression of both urea transporters, SLC14A1 and
SLC14A2, in a panel of human tissues. USG was decreased with each copy of the rs10775480 risk
T allele (p-trend= 0.011) with a significant difference observed for CC vs. TT genotypes (p-
valuetukey=0.024). RNA-sequencing in the bladder tissue showed high expression of SLC14A1
and the absence of SLC14A2, while both transporters were expressed in the kidney. We suggest
that the molecular phenotype of this GWAS finding is the genotype-specific biological activity of
SLC14A1 in the bladder tissue. Our data suggest that SLC14A1 could be a unique urea transporter
in the bladder that has the ability to influence urine concentration and that this mechanism might
explain the increased bladder cancer susceptibility associated with rs10775480.
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INTRODUCTION
Recent results from genome-wide association studies (GWAS) have identified the urea
transporter gene, solute carrier family 14, member 1 (SLC14A1) located on chromosome 18
as a new bladder cancer susceptibility locus.1, 2 The SLC14A1 gene encodes the type B urea
transporter (UT-B) which functions to regulate urine concentration in the kidney and as
determinant of the Kidd (JK) blood group antigen in erythrocytes.3 The GWAS variants tag
the common blood group alleles Jka and JKb as well as the more recently discovered
JKa-weak allele.1 The most associated GWAS variants are intronic single nucleotide
polymorphisms (SNPs) rs7238033, rs10775480 and rs10853535 which capture the
separation of the Jka vs JKb and JKa-weak blood group antigens, defined by the two
functional variants, rs1058396 (Asp280Asn) and rs2298720 (Glu44Lys).1 Information about
the functional consequence of the observed phenotypes with respect to renal function is
minimal. In experimental models using UT-B knockout mouse strains, UT-B null mice had
higher urine volume and lower urine concentration compared to wild-type mice.4 In humans,
carriers of a very rare blood group, JK-null, characterized by the absence of both JKa and
JKb antigens also have impaired urinary concentrating capacity.5 Based on these
observations we hypothesized that bladder cancer risk might be related to a differential
ability of SLC14A1 protein isoforms to transport urea and concentrate the urine.
To examine this hypothesis, we evaluated urine concentration, as measured by specific
gravity,6 in a subset of population-based controls enrolled in the New England Bladder
Cancer Study (NEBCS), which is a part of a bladder cancer GWAS.1;7 Specifically, we
evaluated the relationship between specific gravity and a representative common SNP,
rs10775480 of SLC14A1, which is associated with bladder cancer risk.1 To further explore
and interpret our observations, we performed RNA-sequencing analysis of both human urea
transporter genes, SLC14A1 and SLC14A2, in a panel of human tissues, including kidney
and bladder.
MATERIALS AND METHODS
Study Population and Sample Collection
Details of the NEBCS have been described previously.8 Briefly, the NEBCS is a large
population-based case-control study of 1,193 histologically confirmed cases of urinary
bladder carcinoma (including carcinoma in situ) and 1,418 controls aged 30–79 years living
in Maine, Vermont, and New Hampshire. Subjects were enrolled between September 1,
2001 and October 31, 2004 and were interviewed at home by trained personnel using a
detailed computer-assisted personal interview (CAPI). A standardized, structured
questionnaire elicited demographic data, including current height and weight, as well as
information on major known or suspected risk factors for bladder cancer including
information on smoking, urination frequency at various times of the day and night, history
of urinary tract infection, and usual intake of specific fluids (water, tea, soda, juice, milk,
coffee, alcohol). Approximately 20% of selected subjects provided an overnight urine
sample around the time of interview. Of the 278 controls who provided written informed
consented for specimen collection, an overnight urine sample was collected from 275
(participation rate=98.9%). All collection materials were provided, including a cooler and
ice pack to cool the sample until pick-up by the interviewer at a pre-determined date.
Subjects were asked to begin collecting urine after their evening meal up until and including
the first morning void the next day. A questionnaire to document food and fluid
consumption, smoking status, vitamin intake, and medication use for the two days preceding
the overnight urine collection was also included for completion. Exfoliated buccal cells for
DNA extraction were collected from mouthwash samples at the time of the CAPI.
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Specific Gravity Assessment
Urine was stored in a cooler until it was picked up by study personnel and transferred to the
repository (SeraCare Life Sciences, Inc.). Immediately upon arrival the volume of the urine
was recorded and pH was determined, then aliquots were prepared and samples were
transferred to −80°C for storage. For specific gravity measurements, 1.8 ml aliquots were
thawed and urinary specific gravity was measured by refractometer (also at SeraCare Life
Sciences, Inc.) for all 275 samples.
Genotyping
DNA was extracted from exfoliated buccal cells using standard phenol-chloroform
extraction methods. The samples were genotyped by the Cancer Genetics Research
Laboratory of the Division of Cancer Epidemiology and Genetics of the National Cancer
Institute as a part of a bladder cancer GWAS.1, 7 Three GWAS variants, rs7238033,
rs10775480 and rs10853535, provide similar association with bladder cancer and capture the
separation of Jka vs JKb and JKa-weak blood group antigens, defined by the two functional
variants, rs1058396 (Asp280Asn) and rs2298720 (Glu44Lys). SNP rs10775480 was used
for this study as a representative variant to derive information on Jk blood antigens, which
otherwise could be obtained by genotyping of rs1058396 (Asp280Asn) and rs2298720
(Glu44Lys).1
RNA-sequencing
RNA-sequencing (RNAseq) of seven tumor and five adjacent normal bladder tissue samples
has been previously described.9 Briefly, 1 μg of each total RNA sample was used for polyA
mRNA selection and fragmentation, followed by ligation to 65-bp paired-end adaptors. Each
library was enriched by 12 cycles of PCR and run at a concentration of 4.5 pM on
HiSeq2000 Sequencing Systems (Illumina Inc.) using one lane per sample. On average, 52
million paired 107-bp reads were generated for each sample. All sequencing reads were
processed and aligned to the UCSC Homo sapiens reference genome (hg19) by TopHat
v1.2.0,10 allowing a maximum of two mismatches with the reference sequence. RNA-
sequencing data for all other human samples are a part of Illumina’s Human BodyMap 2.0
project (NCBI GEO GSE30611). All RNA-seq results were visualized using Integrative
Genomics Viewer.11
Statistical Analysis
Univariate linear regression analyses were used to identify predictors of overnight specific
gravity, including all relevant available variables in the CAPI and the overnight urine
collection questionnaire. Important predictors included: age, gender, urination frequency
after dinner (as assessed on CAPI), current body weight (kg), volume of the overnight urine
(mL), and amount of total fluids consumed (as assessed on CAPI). Appropriate
transformations of variables were performed and Spearman correlation coefficients were
used to assess correlations between variables. Analysis of covariance (ANCOVA) was used
to estimate adjusted least square means for specific gravity by rs10775480 genotype.
Variables identified as important predictors of specific gravity were then included as
possible covariates in ANCOVA models and the most parsimonious model was selected.
The final model covariates included age, gender, current weight, and overnight urine
volume. All appropriate regression diagnostics were performed to assess model fit.
Comparisons between adjusted means were performed using unadjusted and multiple
comparison adjustment methods (Tukey). Stratified analyses were also conducted for all
predictive variables. All statistical analyses were performed using SAS software version 9.2
(SAS Institute, Inc., Cary, NC).
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RESULTS
Controls selected for overnight urine collection were representative of the total control
population of the NEBCS (Table 1); they tended to be between 65–74 years of age, male,
white, and former smokers. All of the overnight specific gravity measurements were within
the biologically plausible range. The minor allele frequency of rs10775480 (risk T allele) in
this set was 0.46 and similar to that observed in the whole GWAS set of controls (0.43).1
Adjusted mean values of overnight specific gravity among NEBCS controls in relation to
rs10775480 genotype are presented in Table 2. Individuals with the CC genotype had the
highest adjusted mean levels of urinary specific gravity (1.016, standard error = 0.00056).
Carriage of one or two of the rs10775480 risk alleles (T) resulted in decreased urinary
specific gravity, 1.0154 and 1.0139 respectively (p-trend= 0.011), with a significant
difference observed in adjusted specific gravity means for CC vs. TT genotypes (p-
valuetukey=0.024). Stratified analyses consistently showed the lowest adjusted mean specific
gravity levels among those with the homozygous variant genotype, however, none of the
interactions were statistically significant (data not shown).
We performed RNA-sequencing analysis of the 600-Kb region covering SLC14A1 and
SLC14A2 genes on chr18q12.3 in a panel of human tissues (Illumina’s Human Body Map
project) including normal bladder and tumor samples. This analysis showed that SLC14A2
was mainly expressed in the kidney and breast, but not in the bladder. SLC14A1 was found
to be expressed in several tissues, including normal and human bladder, prostate and brain,
and weaker expression was detected in the kidney (Figure 1).
DISCUSSION
In a subset of 275 controls with overnight urine collection enrolled in a population-based
case-control study of bladder cancer, we observed differential urine concentrations, as
measured by specific gravity, by bladder cancer susceptibility SNP rs10775480 within
SLC14A1. Specifically, carriage of the bladder cancer risk allele resulted in a significant
decrease in urinary specific gravity after controlling for all available predictors. These
results suggest a link between urine concentration and susceptibility to bladder cancer.
In bladder carcinogenesis, the carcinogenic stimulus is believed to be presented to the
urothelium through the urine; this concept is also known as the urogenous contact
hypothesis.12 Based on this hypothesis, active carcinogens dissolved in urine come in
contact and transform cells of bladder epithelium. Thus, factors affecting urine volume and
concentration, including urination frequency and fluid intake, have been evaluated as risk
factors for the disease in epidemiologic studies. Increased fluid intake has been related to
bladder cancer but with inconsistent results with some studies finding a decreased risk,13–15
some a positive risk,16 and others showing no effect.17–20 The impact of urination frequency
on bladder carcinogenesis has also been equivocal17, 18, 21, 22 likely because of the complex
interrelationship between urine concentration, fluid intake, and urination habits. No study, to
our knowledge, has specifically evaluated urine concentration and risk of bladder cancer.
Based on the previous observations that individuals with the extremely rare JK-null blood
group, defined by SLC14A1, are unable to efficiently concentrate the urine, we
hypothesized that bladder cancer risk might be related to this impaired urine concentrating
ability. To test this hypothesis, we examined urine specific gravity, a measure of urine
concentration, in 275 controls with genotype data. We observed a significantly decreased
specific gravity with every copy of the risk allele T of rs10775480, which was independent
of urination frequency, fluid intake and could not be explained by urine volume. We also
examined the expression of both SLC14A1 and SLC14A2 in a panel of human tissues, and
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found SLC14A2 expression predominantly in the kidney, while SLC14A1 was found in
several tissues, including the bladder, with similar expression pattern in normal and
cancerous urothelial tumor tissue. These data suggest that SLC14A1 is a unique urea
transporter in the bladder that has the ability to influence urine concentration. The
composition of urine in the bladder is thought to reflect that produced by the kidney
however, our data suggests, and others have shown,23, 24 that the urothelium has a
significant transport function resulting in the ability to change urine composition.25 This
transport might also allow for the co-transfer of other carcinogenic compounds present in the
urine directly to the bladder epithelium which may increase bladder cancer risk. The exact
mechanism for bladder carcinogenicity is unclear as several mechanisms including direct
carcinogenicity to the urothelium, the interaction of carcinogens with either urinary proteins
or urothelial surface molecules, or the interaction of growth factors with their receptor have
been postulated even for well-established bladder carcinogens.26
Although there is limited experimental evidence, alternative mechanisms have also been
proposed. For example, there is some experimental evidence suggesting that increased
urinary volume (which is coupled with a decrease in specific gravity) may be a risk factor
for bladder carcinogenesis.27 Increased volume of urine is thought to produce distention of
the urothelium, which is coupled with an increase in the number of urothelial cells to
compensate for the increased surface area of the bladder lumen and an increase in cellular
proliferation, which may promote carcinogenesis.26 Our results suggest lower urine
concentration, independent of urine volume, is a molecular phenotype of the genetic
association with bladder cancer risk in SLC14A1. This, and other potential mechanisms,
needs further evaluation in future experimental studies.
Our study has several strengths. We were able to account for important determinants of
specific gravity using detailed collection of urination frequency and fluid intake information
from questionnaires. In addition, information on medical history, medication use, body mass
index, bladder cancer risk factors, and a range of other demographic and lifestyle variables
were available for exhaustive confounding characterization and adjustment. In this study, we
measured specific gravity, which is readily used to evaluate the kidney’s ability to dilute or
concentrate urine in order to maintain homeostasis. An alternative measure, urine
osmolality, is also used to measure the concentrating ability of the kidneys;6 however, we
did not measure osmolality in the NEBCS. Previous studies have shown osmolality to
correlate well with specific gravity measured by refractometry (R2= 0.89–0.96),28, 29 thus
we expect these two measures to be very similar in this population of healthy controls. We
also must consider that the observed association could be due to chance since this is, to our
knowledge, the first study to test this phenotype in relation to SLC14A1. Replication of
these findings is warranted. Our study provides the first indirect evidence that these
functional differences exist, but specifically designed in-vitro biochemical experiments
using allele-specific protein isoforms of SLC14A1 corresponding to all Jk antigens and
measuring minute and transient changes in extracellular and intracellular urea concentration
are needed.
In conclusion, we observed that carriage of the bladder cancer risk variant T allele of
rs10775480 in the urea transporter SLC14A1 is associated with a significant decrease in
urine concentration (i.e. urinary specific gravity). Previous data have linked impaired
urinary concentrating capacity to those lacking UT-B protein which is coded by SLC14A1.
Here we suggest that common variation in this region also impacts urinary concentrating
capacity as well as bladder cancer risk. More work is needed to understand the specifics of
the mechanism due to the complex interrelationship between several determinants of urine
concentration.
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Novelty and impact: In this study we report a novel association between urine
concentration, as measured by urinary specific gravity, and the bladder cancer
susceptibility locus rs10775480 in SLC14A1. Our data suggest that SLC14A1 could be a
unique urea transporter in the bladder that has the ability to influence urine concentration
and ultimately bladder cancer susceptibility.
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Figure 1.
RNA-sequencing results for the 600-Kb genomic region which includes SLC14A2 and
SLC14A1 urea transporters on chr18q13.2 in a panel of human tissues from the Illumina’s
Human BodyMap 2.0 project and in normal and tumor bladder tissue samples. SLC14A2
expression is detected mainly in breast and kidney tissue, but not in the bladder. SLC14A1 is
expressed in several tissues, including normal and human bladder, prostate and brain, and
weaker expression was detected in kidney.
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Table 1
Characteristic of controls in the New England Bladder Cancer Study
Characteristic All Controls
n=1,418
n (%)
Controls with Specific Gravity*
Measurement n=275
n (%)
Age
  <55 255 (18.0) 45 (16.4)
  55–64 336 (23.7) 61 (22.2)
  65–74 544 (38.3) 122 (44.4)
  75+ 283 (20.0) 47 (17.1)
Gender
  Male 1039 (73.3) 195 (70.9)
  Female 379 (26.7) 80 (29.1)
Race/Ethnicity
  White 1371 (96.7) 257 (93.5)
  Other 47 (3.3) 18 (6.5)
State
  Maine 740 (52.2) 153 (55.6)
  Vermont 252 (17.8) 45 (16.4)
  New Hampshire 426 (30.0) 77 (28.0)
Smoking Status
   Occasional Smoker 40 (2.8) 6 (2.2)
   Non-smoker 472 (33.3) 90 (32.7)
   Former smoker 699 (49.3) 140 (50.9)
   Current smoker 206 (14.5) 38 (13.8)
   Unknown 1 (0.07) 1 (0.4)
Current Weight (kg)
  Median (IQR) 81.6 (71.2–93.4) 81.6 (70.3–95.3)
Specific Gravity*
  Median (IQR) -- 1.0150 (1.0109–1.0200)
Urine Volume (mL)
  Median (IQR) -- 811 (561–1311)
rs10775480
  CC 321 (22.6) 71 (25.8)
  CT 549 (38.7) 116 (42.2)
  TT 220 (15.5) 52 (18.9)
  Missing 328 (23.1) 36 (13.1)
    Minor allele frequency (T) 0.45 0.46
Percents may not sum to 100 due to rounding. Abbreviations: Inter-quartile range (IQR).
*Specific gravity of urine from overnight sample.
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Table 2
Adjusted specific gravity means by SLC14A1 rs10775480 genotype among controls in the New England
Bladder Cancer Study
N Adjusted Specific
Gravity Means*
Standard
Error
rs10775480 genotype
  CC 71 1.0160† 0.00056
  CT 116 1.0154† 0.00044
  TT 52 1.0139† 0.00064
p-trend 0.011
*Controlling for age, gender, current weight (kg), and overnight urine volume (mL)
†
Difference between means:
CC vs. CT: p-valueunadjusted = 0.366, p-valuetukey 0.637
CC vs. TT: p-valueunadjusted = 0.009, p-valuetukey 0.024
CT vs. TT: p-valueunadjusted = 0.040, p-valuetukey 0.099
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